Circulating interleukin-10 levels correlate with endotoxemia in chronic liver disease Department of Medicine, University Hospital Innsburck, Innsburck, Austria

Hepatology ◽  
1995 ◽  
Vol 22 (4) ◽  
pp. A499
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Interleukin 10 ◽  
Chronic Liver ◽  
University Hospital

Rhabdomyolysis Associated with Gemfibrozil—Colchicine Therapy

2002 ◽  
Vol 36 (11) ◽  
pp. 1719-1721 ◽  
Author(s):  
Hulusi Atmaca ◽  
Hayriye Sayarlıoğlu ◽  
Eyüp Külah ◽  
Nejat Demircan ◽  
Tekin Akpolat
Keyword(s):  
Liver Disease ◽  
Hepatitis B ◽  
Combination Therapy ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
University Hospital ◽  
Drug Event ◽  
Case Summary ◽  
B Virus ◽  
The University

OBJECTIVE: To report a case of rhabdomyolysis possibly due to combination therapy with colchicine and gemfibrozil. CASE SUMMARY: A 40-year-old man with amyloidosis and hepatitis B virus—related chronic liver disease was admitted to the university hospital because of fatigue, lack of appetite, dark brownish urine, and myalgia for 2 weeks. The patient was receiving colchicine and gemfibrozil. Elevations of serum creatine kinase, lactate dehydrogenase, and aspartate aminotransferase concentrations with myalgia were compatible with the diagnosis of rhabdomyolysis. DISCUSSION: To our knowledge, myopathy and rhabdomyolysis due to a combination of colchicine and gemfibrozil therapy have not been previously reported. Preexisting mild renal failure, hepatitis B—related chronic liver disease, and amyloidosis may be contributing risk factors for the development of rhabdomyolysis in this patient. An objective causality assessment revealed that the adverse drug event was possible. CONCLUSIONS: Patients receiving combination therapy with colchicine and gemfibrozil, especially those with renal and hepatic dysfunction, should be monitored for rhabdomyolysis, and concomitant colchicine and gemfibrozil therapy should be considered in the differential diagnosis of rhabdomyolysis.

Intrahepatic expression of interleukin-10 mRNA in chronic liver disease

1995 ◽  
Vol 108 (4) ◽  
pp. A1059 ◽  
Author(s):  
F.L. Dumoulin ◽  
F. Düx ◽  
L. Leifeld ◽  
H. Herbst ◽  
T. Sauerbruch ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Interleukin 10 ◽  
Chronic Liver

scholarly journals Plasma Arginase-1 Level Is Associated with the Mental Status of Outpatients with Chronic Liver Disease

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 317
Author(s):  
Noriyoshi Ogino ◽  
Fusao Ikeda ◽  
Shihoko Namba ◽  
Shinnosuke Ohkubo ◽  
Tomoaki Nishimura ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Regression Analysis ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Mental Status ◽  
Logistic Regression Analysis ◽  
General Health Questionnaire ◽  
Chronic Liver ◽  
University Hospital ◽  
Arginase 1

While plasma arginase-1 has been suggested as a biomarker of mental status in healthy individuals, it has not been evaluated in patients with chronic liver disease. This cross-sectional study investigated the utility of plasma arginase-1 for screening mental status in patients with chronic liver disease. This study included outpatients with chronic liver disease who underwent regular check-ups at Okayama University Hospital between September 2018 and January 2019. In addition to the standard blood tests, the plasma arginase-1 level was analyzed. The patients’ mental status was assessed using the Japanese version of the General Health Questionnaire-28 (GHQ-28). The associations between mental status and various parameters, including plasma arginase-1, were investigated using logistic regression analysis. Among 114 participating patients, 8 were excluded, comprising 6 with insufficient blood samples for plasma arginase-1 measurement and 2 with incomplete questionnaires. Multivariate binomial logistic regression analysis revealed that plasma arginase-1 was significantly and negatively associated with the GHQ-total score, especially somatic symptoms. Therefore, plasma arginase-1 may be a useful biomarker for assessing the mental status of outpatients with chronic liver disease.

scholarly journals Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease

PLoS ONE ◽  
2021 ◽  
Vol 16 (4) ◽  
pp. e0249435
Author(s):  
Shun-ichi Wakabayashi ◽  
Satoru Joshita ◽  
Kazuhiro Kimura ◽  
Hirohiko Motoki ◽  
Hiroyuki Kobayashi ◽  
...  
Keyword(s):  
Liver Disease ◽  
Survival Rate ◽  
Chronic Liver Disease ◽  
Japanese Patients ◽  
The United States ◽  
Chronic Liver ◽  
University Hospital ◽  
Portopulmonary Hypertension ◽  
Japanese Adult ◽  
Real World Data

Background Portopulmonary hypertension (PoPH) is a subtype of the pulmonary arterial hypertension (PAH) associated with portal hypertension. There is a dissociation between the proportion of PoPH in PAH and that of PoPH in patients with liver cirrhosis, suggesting PoPH underdiagnosis and an incomplete understanding of this entity in the clinical setting. Specifically, real-world data in Japan is largely unknown as compared with in Europe and the United States. The present study aims to elucidate the prevalence and etiology of PoPH in Japanese patients with chronic liver disease. Methods and design In this prospective, single-center, observational investigation of PoPH patients with chronic liver disease, a targeted 2,500 Japanese adult patients regularly visiting Shinshu University Hospital in Matsumoto, Japan, for chronic liver disease will complete a standardized questionnaire on the presence of PoPH symptoms. If the respondent has signs of possible PoPH, ultrasound echocardiography (UCG) will be performed as a primary screening. In the case that UCG findings indicate pulmonary hypertension, the patient will be referred to a cardiologist for further evaluation, whereby a definitive diagnosis PoPH can be made. PoPH prevalence and etiology will be investigated at the time of diagnosis. Afterwards, patients with PoPH will be followed for five years for determination of survival rate. Discussion This study will reveal the prevalence, etiology, and 5-year survival rate of PoPH in Japanese patients with chronic liver disease. Trial registration This study is being performed at Shinshu University following registration as UMIN 000042287 on October 29, 2020.

scholarly journals Association of Hyponatremia and Encephalopathy in Patients with Chronic Liver Disease

2017 ◽  
Vol 23 (1) ◽  
Author(s):  
Muhammad Akbar Memon ◽  
Nadeem Memom ◽  
Abdul Qadir ◽  
Abdul Salam Dal
Keyword(s):  
Liver Disease ◽  
Hepatic Encephalopathy ◽  
Chronic Liver Disease ◽  
Serum Sodium ◽  
Serum Sodium Level ◽  
Chronic Liver ◽  
University Hospital ◽  
Diagnostic Laboratory ◽  
Cross Sectional ◽  
Grade 3

<p><strong>Objective</strong>:  To determine the association of hyponatremia in chronic liver disease patients with presentation of hepatic encephalopathy (HE) at Isra university Hospital Hyderabad.<strong></strong></p><p><strong>Methods</strong>:  This study was cross sectional and carried out at medicine and gastroenterology department of Isra university Hospital Hyderabad and MMC Mirpurkhas. Study duration was from September 2015 to March 2016. All the cases with age more than 25 years, both genders after diagnosis of chronic liver disease with sign and symptoms of Hepatic Encephalopathy were selected in this study. Blood sample for serum sodium level, was send to diagnostic laboratory of the hospital. Hyponatremia was classified as: 130–135 mEqL (mild), 125–130 mEq/L (moderate) and &lt; 125 mEq/L (severe). Hepatic encephalopathy was categorized according to the West Haven classification (4 grades).</p><p> </p><p><strong>Results:</strong><strong>  </strong>Total number of cases was 80. Mean age was 48 + 8.5 years. 55 (68.5%) patients were male. Majority of cases, 55 (68.5%) patients were infected with HCV. 40% patients had normal level of sodium, 25% had mild, 20% had moderate while 15% patients had severe hyponatremia. On the grading of encephalopathy, 30 (37.5%) patients had grade 1 encephalopathy while 25/(31.2%) patients had grade 2, 15/(18.8%) had grade 3 while 10 (12.5%) patients hade grade 4. The serum sodium levels significantly decreased with increasing severity of hepatic encephalopathy (P = 0.001).</p><p><strong>Conclusion:</strong><strong>  </strong>We concluded that the hyponatremia is significantly linked with Hepatic Encephalopathy (HE) in patients having chronic liver disease (CLD).</p>

scholarly journals CHRONIC LIVER DISEASE

2018 ◽  
Vol 25 (02) ◽  
pp. 292-296
Author(s):  
Ahsan Mobin ◽  
Imtiaz Manzoor ◽  
Hafeezullah Shaikh ◽  
Muhammad Ashraf Ebrahim
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Complete Blood Count ◽  
Case Series ◽  
Abdominal Ultrasound ◽  
Chronic Liver ◽  
University Hospital ◽  
Early Management ◽  
Female Ratio ◽  
Case Series Study

Objectives: Objective of this study is to evaluate the frequency of pancytopeniain patients with viral chronic liver disease. Study Design: Descriptive case series study. Setting:All patients enrolled from OPD and admitted patients having a chronic liver disease either dueto HBV or HCV at Dow university hospital, Chiniot General Hospital and Zubaida MedicalCenter Karachi. Period: One year starting from January 2016 to December 2016. Methods: Allpatients regardless of age and gender with chronic liver disease due to Hepatitis B or HepatitisC were included. Patient’s age, duration of illness and previous treatments were recorded alongwith physical examination. Other investigations included complete blood count (CBC) andultrasound abdomen. Patients with history of alcohol intake, upper gastrointestinal bleeding, orany procedure like sclerotherapy or band ligation, currently taking interferon therapy / historyof receiving interferon in the past six months or hepatoma on abdominal ultrasound wereexcluded. Results: Among 224 patients. Male to female ratio was 3.9:1. Mean age was foundto be 40.2+3.21. Majority of individuals were between ages 36-45 years. The minimum age was25 years whereas the maximum age was 65 years. Pancytopenia was found in 28.57 % patients.Conclusion: We have concluded that pancytopenia is common in patients with chronic liverdisease. Early management can prevent deteriorating outcomes.

Sign in / Sign up

Export Citation Format

Share Document